Complex in vitro 3D models of digestive system tumors to advance precision medicine and drug testing: Progress, challenges, and trends

Digestive system cancers account for nearly half of all cancers around the world and have a high mortality rate. Cell culture and animal models represent cornerstones of digestive cancer research. However, their ability to enable cancer precision medicine is limited. Cell culture models cannot retai...

Full description

Saved in:
Bibliographic Details
Published inPharmacology & therapeutics (Oxford) Vol. 239; p. 108276
Main Authors Song, Sheng-Lei, Li, Bo, Carvalho, Mariana R., Wang, Hui-Jin, Mao, De-Li, Wei, Ji-Tao, Chen, Wei, Weng, Zhi-Hui, Chen, Yang-Chao, Deng, Chu-Xia, Reis, Rui L., Oliveira, Joaquim M., He, Yu-Long, Yan, Le-Ping, Zhang, Chang-Hua
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.11.2022
Subjects
cancer-on-a-chip
Digestive system cancer
In vitro 3D models
Organoids
Tumor microenvironment
hHSC
TCR
BE
MDSC
OTSC
2D
Organoids
CAFs
mCRC
In vitro 3D models
PDO
Digestive system cancer
GC
CC
GI
IFN-DCs
Tumor microenvironment
PDX
OOAC
HCC
TIME
TME
hPBMC
3D
hiPSCs
PC
PDAC
HAN
CRC
TCR-T
cancer-on-a-chip
TILs
NK
ALI
DC
Online AccessGet full text

Cover

More Information
Summary:Digestive system cancers account for nearly half of all cancers around the world and have a high mortality rate. Cell culture and animal models represent cornerstones of digestive cancer research. However, their ability to enable cancer precision medicine is limited. Cell culture models cannot retain the genetic and phenotypic heterogeneity of tumors and lack tumor microenvironment (TME). Patient-derived xenograft mouse models are not suitable for immune-oncology research. While humanized mouse models are time- and cost-consuming. Suitable preclinical models, which can facilitate the understanding of mechanisms of tumor progression and develop new therapeutic strategies, are in high demand. This review article summarizes the recent progress on the establishment of TME by using tumor organoid models and microfluidic systems. The main challenges regarding the translation of organoid models from bench to bedside are discussed. The integration of organoids and a microfluidic platform is the emerging trend in drug screening and precision medicine. A future prospective on this field is also provided.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0163-7258
1879-016X
DOI:10.1016/j.pharmthera.2022.108276